基于保守抗原的通用流感疫苗在小鼠中提供持久免疫与广谱保护
该研究在小鼠中评估单剂鼻内接种表达A型流感核蛋白(A/NP)和基质2(M2)的重组腺病毒(rAd)通用流感疫苗候选物的长期免疫效果。结果显示抗体和T细胞应答维持超过一年无需加强,针对1组和2组A型流感病毒的攻击保护持续一年且保持广谱;B型流感核蛋白(B/NP)-rAd免疫也产生持续一年的应答并交叉保护错配HA谱系的B型流感病毒。
要点
- 单剂鼻内rAd-A/NP+M2疫苗在小鼠中诱导抗体和T细胞应答持续超过一年。
- 针对1组和2组A型流感病毒的攻击保护在接种一年后仍存在且广谱。
- B/NP-rAd免疫可保护错配HA谱系的B型流感病毒攻击。
核心结论
- 黏膜接种保守流感抗原可在动物中提供针对广谱A型和B型流感病毒的非常持久免疫保护。
研究设计与样本
- 在小鼠模型中单剂鼻内接种表达A/NP和M2的重组腺病毒(rAd)通用疫苗候选物。
- 扩展研究至B型流感,使用B/NP-rAd免疫并评估一年后的免疫应答和攻击保护。
- 评估初次接种一年后对腺病毒载体抗原已有宿主免疫情况下的再次接种效果。
主要发现
- 抗体和T细胞应答在无需加强的情况下持续超过一年。
- 针对攻击的保护在接种一年后仍存在,且覆盖1组和2组A型流感病毒。
- B/NP-rAd免疫应答持续一年无需加强,并保护错配HA谱系的B型流感病毒攻击。
- 初次接种一年后有效再次接种可行,成功免疫动物未接触过的转基因产物。
- 针对 divergent 和高致病性A/H7N9病毒的攻击保护较弱,但第二剂疫苗可增强。
临床怎么用
- 支持进一步开发基于保守抗原的黏膜通用流感疫苗以实现长期广谱保护。
- 提示单剂鼻内rAd疫苗可能减少对年度毒株匹配和加强接种的依赖。
- 对于高致病性亚型如A/H7N9,可能需要第二剂疫苗增强保护。
局限性
- 研究仅在小鼠模型中进行,结果需在其它动物模型和人体中验证。
- 针对A/H7N9的攻击保护较弱,需额外剂量增强。
- 原文未报告具体样本量、P值或保护效力数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current influenza vaccines rely on inducing antibody responses to the rapidly evolving hemagglutinin (HA) and neuraminidase (NA) proteins, and thus need to be strain-matched. However, predictions of strains that will circulate are imperfect, and manufacturing of new vaccines based on them takes months. As an alternative, universal influenza vaccines target highly conserved antigens. In proof of concept studies of universal vaccine candidates in animal models challenge is generally conducted only a short time after vaccination, but protective immunity lasting far longer is important for the intended public health impact. We address the challenge of providing long-term protection. We demonstrate here broad, powerful, and long-lasting immune protection for a promising universal vaccine candidate. A single intranasal dose of recombinant adenoviruses (rAd) expressing influenza A nucleoprotein (A/NP) and matrix 2 (M2) was used. Extending our previous studies of this type of vaccine, we show that antibody and T-cell responses persist for over a year without boosting, and that protection against challenge persists a year after vaccination and remains broad, covering both group 1 and 2 influenza A viruses. In addition, we extend the work to influenza B. Immunization with influenza B nucleoprotein (B/NP)-rAd also gives immune responses that last a year without boosting and protect against challenge with influenza B viruses of mismatched HA lineages. Despite host immunity to adenoviral antigens, effective readministration is possible a year after primary vaccination, as shown by successful immunization to a transgene product the animals had not seen before. Protection against challenge with divergent and highly pathogenic A/H7N9 virus was weaker but was enhanced by a second dose of vaccine. Thus, this mucosal vaccination to conserved influenza antigens confers very long-lasting immune protection in animals against a broad range of influenza A and B viruses.
引用
- Lo CY, Misplon JA, Li X, et al. Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice. Vaccine. 2021. PMID: 34226103. doi:10.1016/j.vaccine.2021.06.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。